HealthMore in Health→
Angelini Moves to Deepen Rare Neurology Bet With Catalyst Deal
Key Takeaways
- Angelini Pharma is buying Catalyst Pharmaceuticals for $4.1 billion.
- The acquisition would add three FDA-approved rare neurology treatments.
- The deal strengthens Angelini's existing neurology portfolio rather than opening a new therapeutic area.
DE
DT Editorial Team··via endpoints.news
